Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
76.06
+1.26 (+1.68%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
February 20, 2025
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.
Via
Stocktwits
Exposures
Product Safety
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
February 19, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
February 19, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Looking Into Merck & Co's Recent Short Interest
February 18, 2025
Via
Benzinga
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock
February 18, 2025
Via
Benzinga
Why NYSE:MRK is a Top Pick for Dividend Investors.
February 18, 2025
Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals.
Via
Chartmill
Decoding Merck & Co's Options Activity: What's the Big Picture?
February 13, 2025
Via
Benzinga
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
February 19, 2025
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.
Via
Benzinga
Topics
ETFs
Government
World Trade
Exposures
Political
Tariff
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
February 18, 2025
From
Robbins LLP
Via
GlobeNewswire
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock
February 11, 2025
Via
Benzinga
Europe Approves Merck's Cancer Drug For Two Indications
February 18, 2025
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries.
Via
Benzinga
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
February 18, 2025
Via
Benzinga
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
February 18, 2025
Via
Benzinga
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
February 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
February 18, 2025
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.
Via
Benzinga
Topics
Government
Exposures
Political
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 17, 2025
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 17, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 15, 2025
From
The Schall Law Firm
Via
Business Wire
MarketBeat Week in Review – 02/10 - 02/14
February 15, 2025
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in
Via
MarketBeat
Topics
Credit Cards
Economy
Government
Exposures
Interest Rates
Political
Tariff
10 Health Care Stocks With Whale Alerts In Today's Session
February 14, 2025
Via
Benzinga
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
February 14, 2025
MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Via
Chartmill
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 14, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
February 13, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
February 13, 2025
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via
Benzinga
Topics
Government
Exposures
Political
3 Blue-Chip Dividend Stocks Trading at Multiyear Lows
February 13, 2025
Via
The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
February 13, 2025
Via
The Motley Fool
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
February 12, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes
February 12, 2025
This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.
Via
Stocktwits
Gilead Sciences Beats Q4 EPS Forecast
February 11, 2025
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.